Email this article 
10% INTRAVENOUS IMMUNOGLOBULIN GAMUNEX IN THE TREATMENT OF PRIMARY IMMUNODEFICIENCIES PATIENTS: OWN EXPERIENCE AND LITERATURE REVIEW
- Authors: Smirnova IN1, Kosacheva TG1,2, Shvetz OV2, Zimin SB2, Shcherbina AY.1
-
Affiliations:
- Federal Research and Cinical Center for Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Ministry of Health
- Children's City Clinical Hospital No. 9, named after G.N. Speransky
- Issue: Vol 11, No 6 (2014)
- Pages: 76-81
- Section: Articles
- Submitted: 10.03.2020
- Published: 15.12.2014
- URL: https://rusalljournal.ru/raj/article/view/547
- DOI: https://doi.org/10.36691/RJA547
- ID: 547
Cite item
Open Access
Access granted
Abstract
Intravenous immunoglobulin G preparation (IVIG) is an effective and safe therapeutic modality in the primary immunodeficiencies (PID) management. We investigated effectiveness and safety of the 10% preparation of IVIG Gamunex in treatment of 26 patients with primary immunodeficiencies at ages 8 months 17 years. Percentage of nonsevere reactions to Gamunex infusions was similar as to other 5% IVIG preparations (2,9 vs 2,8%). Average time of infusion was reduced from 88 minutes for 5% IVIG to 67 minutes for Gamunex. Average trough IgG level after Gamunex infusions was sufficient (6,8 g/l) and resulted in the absence of significant infectious episodes in PID patients during the study period. Our study demonstrated good efficacy and safety profile of Gamunex.
Full Text
About the authors
I N Smirnova
Federal Research and Cinical Center for Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Ministry of Health
T G Kosacheva
Federal Research and Cinical Center for Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Ministry of Health; Children's City Clinical Hospital No. 9, named after G.N. Speransky
O V Shvetz
Children's City Clinical Hospital No. 9, named after G.N. Speransky
S B Zimin
Children's City Clinical Hospital No. 9, named after G.N. Speransky
A Yur'evna Shcherbina
Federal Research and Cinical Center for Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Ministry of Health
Email: shcher26@hotmail.com
References
- Ochs H.D., Hitzig WюH. History of primary immunodeficiency diseases. Curr. Opin. Allergy Clin. Immunol. 2012, v. 12, р.577-587.
- Hinman J., Tullis J.L., Saravis C.A., Pennell R.B. Intravenous use of plasmin treated immunoglobulin G.I. Preliminary report on tolerance by immunologically deficient patients. Vbx. Sang. 1967, v. 13, р. 85-90.
- Maarschalk-Ellerbroek J., Hoepelman I.M., Ellerbroek P.M. Immunoglobulin treatment in primary antibody deficiency. Int. J. Antimicrob. Agents. 2011, v. 37, р. 396-404.
- Dickler H.B., Gelfand E.W Current perspectives on the use of intravenous immunoglobulin. Adv. Intern. Med. 1996, v. 41, р. 641-680.
- Navarro R.P., Ballow M., Fenrick B., Pezalla E.J. Considerations for optimal use of immunoglobulin. Am. J. Manage Care. 2012, v. 18, р. 67-78.
- Aukrust P., Froland S.S., Liabakk N.B. et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood. 1994, v. 84, р. 136-143.
- Eijkhout H.W., van der Meer J.W.M., Kallenberg C.G.M. et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. Ann. Intern. Med. 2001, v. 135, р. 165-174.
- Orange J.S., Grossman W.F., Navickis R.J., Wilkes M.M. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin. Immunol. 2010, v. 137, p. 21-30.
- Roifman C.M., Schroeder H., Berger M. et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int. Immunopharmacol. 2003, v. 3, р. 1325-1333.
- Ballow M., Berger M., Bonilla F.A. et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox. Sang. 2003, v. 84, р. 202-210.
- Teschner W., Butterweck H.A., Auer W. et al. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process. Vox. Sang. 2007, v. 92, р. 42-55.
- Lundblad J.L., Seng R. Inactivation of lipid-enveloped viruses in proteins with caprylate. Vox. Sang. 1991, v. 60, р. 75-81.
- Lebing W., Remington K.M., Schreiner C., Paul H.I. Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography. Vox. Sang. 2003, v. 84, р. 193-201.
Supplementary files
